Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Scabies diagnoses in Catalonia during and after the COVID-19 pandemic: a primary care time-series analysis.

Created on 24 Jul 2026

Authors

Núria Mora, Leonardo Méndez-Boo, Aida Perramón-Malavez, Carolina Guiriguet, Eduardo Hermosilla, Mireia Fábregas, Francisca Ramos, Francesc Fina, Ermengol Coma

Published in

Gaceta sanitaria. Volume 40. Pages 102637. Jul 23, 2026. Epub Jul 23, 2026.

Abstract

To assess trends and excess of recorded scabies diagnoses in Catalonia before and after the COVID-19 pandemic.
Population-based time-series study using primary care electronic health records of scabies diagnosis from January 2014 to December 2024. Expected monthly rates of recorded diagnoses were estimated with a time-series regression model including a linear time trend and monthly seasonal components, fitted with 2014-2018 data as the reference pre-pandemic period. Excess was calculated overall and stratified by age, sex, and socioeconomic status.
Among 254,941 diagnoses, 83.8% occurred since 2020. Monthly rates increased from 4-16 cases per 100,000 in 2014-2017 to 117 in 2023. Annual excesses were 14.8% in 2020, 118.6% in 2021, 281.6% in 2022, and 318.9% in 2023. All socioeconomic and age groups were affected.
Recorded scabies diagnoses rate increased markedly after the pandemic and remained above expected levels through 2024, highlighting the need for strengthened surveillance and control strategies.

PMID:
42492139
Bibliographic data and abstract were imported from PubMed on 24 Jul 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 4
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement